Research programme: genetically modified skin replacement therapy - Stratatech

Drug Profile

Research programme: genetically modified skin replacement therapy - Stratatech

Alternative Names: EpiReady; ExpressGraft™; ExpressGraft™ - Antineoplastic; ExpressGraft™ - Pro-angiogenic; ExpressGraft™ Enhance

Latest Information Update: 02 Sep 2016

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Wisconsin Alumni Research Foundation
  • Developer Stratatech
  • Class Cell therapies; Gene therapies
  • Mechanism of Action Cathecilidin expression stimulants; Gene transference; Interleukin-12 expression stimulants; Tissue replacements; Vascular endothelial growth factor A expression stimulants
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Research Skin cancer
  • No development reported Skin ulcer

Most Recent Events

  • 31 Aug 2016 Stratatech has been acquired by Mallinckrodt plc
  • 16 Jul 2016 No recent reports of development identified for preclinical development in Skin-ulcer in USA (Topical, Patch)
  • 05 Aug 2013 Early research in Skin cancer in USA (Topical)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top